EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Usage status of biologics for the chronic treatment of optic neuritis in neuromyelitis optica spectrum disorders in Japan

Yohei Takahashi, Takeshi Kezuka, Keigo Shikishima, Akiko Yamagami, Hideki Chuman, Makoto Nakamura, Satoshi Ueki, Akiko Kimura, Masato Hashimoto, Sonoko Tatsui, Kimiyo Mashimo, Hitoshi Ishikawa

Japanese Journal of Ophthalmology · 2025

DOI: 10.1007/s10384-024-01129-4 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Japanese Journal of Ophthalmology, 2025. Verfasst von Yohei Takahashi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Kitasato University School of Medicine, 1-15-1 Kitazato, Minami-ku, Sagamihara-shi, Kanagawa, 252-0373, Japan. ytakahash…. Hauptthemen laut MEDLINE: Optic Neuritis, Neuromyelitis Optica, Biological Products, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To investigate the usage status of biologics for the chronic treatment of optic neuritis including neuromyelitis optica spectrum disorders in Japan.

Design

Multicenter retrospective case series.

Methods

Patients diagnosed with anti-aquaporin 4 antibody (AQP4-Ab) positive optic neuritis and had been initiated on biologics (satralizumab, eculizumab, and inebilizumab) between January 2020 and August 2022 were identified at 30 facilities in Japan. These patients were investigated regarding changes in oral steroid doses, optic neuritis relapse, and adverse events after initiation of biologics.

Results

Eighty-eight patients with AQP4-Ab positive optic neuritis initiated on biologics were included. Satralizumab was the most common biologic used (79 patients), followed by eculizumab (6 patients) and inebilizumab (3 patients). In the satralizumab group, during the observation period (10.0±7.0 months) until February 2023, the oral steroid dose was reduced significantly from 13.8 ± 8.6 mg/day at the time of initiation to 5.3 ± 4.8 mg/day (p < 0.001). No relapse of optic neuritis was observed in 76 of 79 patients (96.2%) after initiation of satralizumab. Furthermore, in 15 patients who succeeded in discontinuing steroids during 8.5 ± 5.8 months after initiation of satralizumab, no relapse of optic neuritis was observed throughout the observation period. Adverse events occurred in 7 patients with satralizumab and 2 patients with eculizumab, but no serious infections were observed.

Conclusions

Satralizumab was the most commonly used biologic for AQP4-Ab positive optic neuritis in Japan. This study demonstrates the efficacy and safety of satralizumab in preventing the relapse of optic neuritis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Optic NeuritisNeuromyelitis OpticaBiological ProductsAntibodies, Monoclonal, HumanizedHumansRetrospective StudiesJapanFemaleMaleAdultMiddle AgedFollow-Up StudiesAquaporin 4AgedTreatment OutcomeChronic Disease

Stichwörter der Autor:innen

BiologicsNeuromyelitis optica spectrum disordersOptic neuritisOral steroidSatralizumab

Substanzen

Biological ProductsAquaporin 4eculizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Ophthalmology, Kitasato University School of Medicine, 1-15-1 Kitazato, Minami-ku, Sagamihara-shi, Kanagawa, 252-0373, Japan. ytakahashi19870715@gmail.com.
  • Department of Ophthalmology, Tokyo Women's Medical University, Tokyo, Japan. ytakahashi19870715@gmail.com.
  • Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.
  • Department of Ophthalmology, The Jikei University School of Medicine, Tokyo, Japan.
  • Inouye Eye Hospital, Tokyo, Japan.
  • Department of Ophthalmology, University of Miyazaki, Miyazaki, Japan.

Zitieren

APA

Takahashi, Y., Kezuka, T., Shikishima, K., Yamagami, A., Chuman, H., Nakamura, M., Ueki, S., Kimura, A., Hashimoto, M., Tatsui, S., Mashimo, K., & Ishikawa, H. (2025). Usage status of biologics for the chronic treatment of optic neuritis in neuromyelitis optica spectrum disorders in Japan. Japanese Journal of Ophthalmology. https://doi.org/10.1007/s10384-024-01129-4

Vancouver

Takahashi Y, Kezuka T, Shikishima K, Yamagami A, Chuman H, Nakamura M, et al. Usage status of biologics for the chronic treatment of optic neuritis in neuromyelitis optica spectrum disorders in Japan. Japanese Journal of Ophthalmology. 2025. doi:10.1007/s10384-024-01129-4

BibTeX
@article{Takahashi2025,
  author = {Takahashi, Yohei and Kezuka, Takeshi and Shikishima, Keigo and Yamagami, Akiko and Chuman, Hideki and Nakamura, Makoto and Ueki, Satoshi and Kimura, Akiko and Hashimoto, Masato and Tatsui, Sonoko and Mashimo, Kimiyo and Ishikawa, Hitoshi},
  title = {Usage status of biologics for the chronic treatment of optic neuritis in neuromyelitis optica spectrum disorders in Japan},
  journal = {Japanese Journal of Ophthalmology},
  year = {2025},
  doi = {10.1007/s10384-024-01129-4}
}
Kostenlos starten →